Thermo Fisher Scientific Inc. $TMO Shares Purchased by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.5% during the 3rd quarter, Holdings Channel reports. The firm owned 7,688 shares of the medical research company’s stock after purchasing an additional 1,144 shares during the period. Farther Finance Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,729,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of TMO. TIAA Trust National Association boosted its holdings in shares of Thermo Fisher Scientific by 10.5% in the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after buying an additional 11,817 shares during the period. Lombard Odier Asset Management Switzerland SA lifted its position in shares of Thermo Fisher Scientific by 8.4% in the 2nd quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock valued at $5,875,000 after acquiring an additional 1,128 shares in the last quarter. Caledonia Investments PLC boosted its stake in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after purchasing an additional 11,500 shares during the period. Heritage Investors Management Corp grew its position in Thermo Fisher Scientific by 9.6% during the 2nd quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock worth $22,944,000 after purchasing an additional 4,971 shares in the last quarter. Finally, LBP AM SA raised its stake in Thermo Fisher Scientific by 13.4% during the 2nd quarter. LBP AM SA now owns 261,038 shares of the medical research company’s stock valued at $105,840,000 after purchasing an additional 30,837 shares during the period. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Wells Fargo & Company increased their target price on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, UBS Group lifted their target price on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $616.60.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 17,104 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This represents a 36.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 149,271 shares of company stock worth $86,507,282 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $581.50 on Thursday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $218.48 billion, a PE ratio of 33.59, a price-to-earnings-growth ratio of 4.12 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a 50 day moving average price of $572.21 and a two-hundred day moving average price of $501.13.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.